SELLAS Life Sciences Group (NASDAQ:SLS) Releases Earnings Results, Hits Estimates

SELLAS Life Sciences Group (NASDAQ:SLS) announced its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05), FiscalAI reports.

SELLAS Life Sciences Group Stock Performance

SLS traded down $0.39 during trading on Thursday, reaching $8.03. 3,824,042 shares of the stock were exchanged, compared to its average volume of 7,847,869. The stock has a market cap of $1.62 billion, a P/E ratio of -38.24 and a beta of 2.73. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $15.88. The stock’s 50 day moving average price is $11.27 and its two-hundred day moving average price is $8.74.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SLS. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.